AJP - Gastrointestinal and Liver Physiology, Vol 258, Issue 4 527-G534, Copyright © 1990 by American Physiological Society

ARTICLES

An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis

J. L. Wallace and C. M. Keenan
Gastrointestinal Research Group, University of Calgary, Alberta, Canada.

Leukotrienes (LTs) have been implicated as mediators of the inflammation and ulceration associated with ulcerative colitis and Crohn's disease. In the present study, the effects of a novel, orally active inhibitor of LT synthesis (MK-886) were examined in a rat model of chronic colitis. Colitis was induced by intracolonic administration of trinitrobenzenesulfonic acid. Colonic LTB4 synthesis was measured after incubation of tissue samples in vitro and by in vivo equilibrium dialysis. A single dose of MK-886 (10 mg/kg) significantly inhibited colonic LTB4 synthesis for greater than 24 h. Daily treatment with this dose significantly reduced colonic damage, as assessed macroscopically and histologically, when the treatment was performed 2 h before induction of colitis and daily thereafter for 1 wk, but not when treatment was performed during the second week after induction of colitis. A less marked beneficial effect of MK-886 was observed when the pretreatment dose was excluded, suggesting a role for LTs in the early events of the inflammatory process. Inhibition of LT synthesis during the first 24 h after induction of colitis did not alter the extent of infiltration of neutrophils into the colon, as measured by tissue myeloperoxidase activity. Daily treatment with sulfasalazine (100 mg/kg po) either during the first or second week after induction of colitis did not significantly affect the rates of healing. At the dose used, sulfasalazine only produced a transient inhibition of colonic LTB4 synthesis. This study therefore demonstrates that a specific, orally active inhibitor of LT synthesis can significantly accelerate healing in this animal model of colitis when the treatment is performed during the early phase of the inflammatory response.

This article has been cited by other articles:

				C. Daniel, N. A. Sartory, N. Zahn, H. H. Radeke, and J. M. Stein Immune Modulatory Treatment of Trinitrobenzene Sulfonic Acid Colitis with Calcitriol Is Associated with a Change of a T Helper (Th) 1/Th17 to a Th2 and Regulatory T Cell Profile J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 23 - 33. [Abstract] [Full Text] [PDF]

				B. A. Vallance, M. I. Gunawan, B. Hewlett, P. Bercik, C. Van Kampen, F. Galeazzi, P. J. Sime, J. Gauldie, and S. M. Collins TGF-{beta}1 gene transfer to the mouse colon leads to intestinal fibrosis Am J Physiol Gastrointest Liver Physiol, July 1, 2005; 289(1): G116 - G128. [Abstract] [Full Text] [PDF]

				P. R. Kiela, A. J. Midura, N. Kuscuoglu, S. D. Jolad, A. M. Solyom, D. G. Besselsen, B. N. Timmermann, and F. K. Ghishan Effects of Boswellia serrata in mouse models of chemically induced colitis Am J Physiol Gastrointest Liver Physiol, April 1, 2005; 288(4): G798 - G808. [Abstract] [Full Text] [PDF]

				C. Van Kampen, J. Gauldie, and S. M. Collins Proinflammatory properties of IL-4 in the intestinal microenvironment Am J Physiol Gastrointest Liver Physiol, January 1, 2005; 288(1): G111 - G117. [Abstract] [Full Text] [PDF]

				J. R. Scott and A. E. Fox-Robichaud Hepatic leukocyte recruitment in a model of acute colitis Am J Physiol Gastrointest Liver Physiol, September 1, 2002; 283(3): G561 - G566. [Abstract] [Full Text] [PDF]

				I. Topilski, A. Harmelin, R. A. Flavell, Y. Levo, and I. Shachar Preferential Th1 Immune Response in Invariant Chain-Deficient Mice J. Immunol., February 15, 2002; 168(4): 1610 - 1617. [Abstract] [Full Text] [PDF]

				J. L. Wallace and L. Ma Inflammatory Mediators in Gastrointestinal Defense and Injury Experimental Biology and Medicine, December 1, 2001; 226(11): 1003 - 1015. [Abstract] [Full Text] [PDF]

				H. Nakase, K. Okazaki, Y. Tabata, S. Uose, M. Ohana, K. Uchida, T. Nishi, A.'s Debreceni, T. Itoh, C. Kawanami, et al. An Oral Drug Delivery System Targeting Immune-Regulating Cells Ameliorates Mucosal Injury in Trinitrobenzene Sulfonic Acid-Induced Colitis J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1122 - 1128. [Abstract] [Full Text]

				C. Bossone, J. M. Hosseini, V. Pineiro-Carrero, and T. Shea-Donohue Alterations in spontaneous contractions in vitro after repeated inflammation of rat distal colon Am J Physiol Gastrointest Liver Physiol, May 1, 2001; 280(5): G949 - G957. [Abstract] [Full Text] [PDF]

				S Pathmakanthan and C J Hawkey A lay doctor's guide to the inflammatory process in the gastrointestinal tract Postgrad. Med. J., October 1, 2000; 76(900): 611 - 617. [Full Text]

				C J Bell, E J Elliott, J L Wallace, D M Redmond, J Payne, Z Li, and E V O'Loughlin Do eicosanoids cause colonic dysfunction in experimental E coli 0157:H7 (EHEC) infection? Gut, June 1, 2000; 46(6): 806 - 812. [Abstract] [Full Text] [PDF]

				G Barbara, Z Xing, C M Hogaboam, J Gauldie, and S M Collins Interleukin 10 gene transfer prevents experimental colitis in rats Gut, March 1, 2000; 46(3): 344 - 349. [Abstract] [Full Text] [PDF]

				C P Tran, G A Cook, N D Yeomans, L Thim, and A S Giraud Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis Gut, May 1, 1999; 44(5): 636 - 642. [Abstract] [Full Text] [PDF]

				C. A. Hathaway, C. B. Appleyard, W. H. Percy, and J. L. Williams Experimental colitis increases blood-brain barrier permeability in rabbits Am J Physiol Gastrointest Liver Physiol, May 1, 1999; 276(5): G1174 - G1180. [Abstract] [Full Text] [PDF]

				J. L. Wallace, W. McKnight, S. Asfaha, and D. Y. Liu Reduction of acute and reactivated colitis in rats by an inhibitor of neutrophil activation Am J Physiol Gastrointest Liver Physiol, May 1, 1998; 274(5): G802 - G808. [Abstract] [Full Text] [PDF]